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Objective: To examine differences in the proportions of
people diagnosed with pancreatic cancer who underwentThe known Pancreatectomy is a complex procedure that
requires multidisciplinary specialist care. It is reportedpancreatectomy, post-operative outcomes and 5-year survival in
different New South Wales administrative health regions of
residence.
Design, setting and participants: Retrospective analysis of
NSW data on pancreatic cancer incidence and surgery,
2005e2013.
Main outcome measures: The proportion of newly diagnosed
patients with pancreatic cancer who were resected in each
region; 90-day post-operative mortality; one-year




internationally that pancreatectomy is underused.
The new The pancreatectomy rate is low in some NSW areas,
and the difference in rates is clinically significant.
The implications Population-level survival for patients with
pancreatic cancer could be improved by increasing resection
rates. Improving awareness of and access to specialist
centres with the resources for managing complex cases
would facilitate this increase. Given the geographic and
socio-demographic challenges to providing such access, a
whole-of-system approach that links primary and tertiary care
is needed, as well as patient information and support.Results: 14% of people diagnosed with pancreatic cancer during
2010e2013 (431 of 3064) underwent pancreatectomy, an
average of 108 resections per year. After adjusting for age, sex
and comorbidities, the proportion that underwent resection
varied significantly between regions, ranging between 8% and
21% (P<0.001). Higher resection rates were not associated withancreatic cancer is the fourth most common cause of
cancer-related death for men and women in Australia.1higher post-operative 90-day mortality or lower one-year
survival (unadjusted and risk-adjusted analyses). Higher
resection rates were associated with higher 5-year
post-diagnosis survival: the mean survival in regions with
resection rates below 10% was 3.4%, compared with 7.2% in
regions with rates greater than 15% (unadjusted and adjusted
survival analyses; P<0.001). There was a positive association
between regional resection rate and the pancreatectomy volume
of hospitals during 2005e2009. An additional 32 people would
be resected annually if resection rates in low rate regions were
increased to the 80th percentile regional resection rate (18%).
Conclusion: There is significant geographic variation in the
proportion of people with pancreatic cancer undergoing
pancreatectomy, and the 5-year survival rate is higher in regions
















17PThe 5-year post-diagnosis survival rate is the lowest of
any cancer in New South Wales (6%) or Australia (5%).1,2
Reasons for low survival include the high rates of presentation
at an advanced stage of disease and the lack of effective systemic
therapies.
Survival for people presenting with loco-regional disease can be
improved by surgical resection.3,4 However, there is international
evidence that surgical resection is underused in patients with
pancreatic cancers.3 When leading surgeons were told of variation
between NSW Local Health Districts (hereafter: “regions”) in the
resection rate of residents diagnosed with pancreatic cancer, the
two major responses were that regions with higher resection rates
may select patients inappropriately, increasing short term
morbidity and mortality; and that not enough people were being
offered surgery, compromising long term survival across the
population. Our study assessed the relative merits of these two
positions.
We firstly assessed variation between regions in the resection rate,
with unexplained variation potentially reflecting systemic varia-
tion in the use of pancreatectomy. We then examined two
hypotheses:
 The regional pancreatic cancer resection rate does not influ-
ence short term post-operative outcomes. If higher pro-
portions of people being resected were associated with poorer
post-operative outcomes, it may indicate clinically futile
surgery in some people.
 The regional pancreatic cancer resection rate does not influ-
ence long term survival. If survival were higher in regions
with higher proportions of people being resected, it would
suggest that resection is systematically underused.ancer Institute New South Wales, Sydney, NSW. 2Centre for Population Health Research
Westmead Hospital, Sydney, NSW. 5Sydney Medical School, Sydney, NSW. 6University
oi: 10.5694/mja16.00150 j See Editorial, p. 21We also explored institutional pancreatectomy caseload as a factor
that potentially influences resection rates, as it is amodifiable factor
in the context of system performance improvement.
Methods
Our cohort study analysed de-identified, linked, population-based
cancer registry and hospital data. Cancer incidence and surgery
data for 2005e2013 were ascertained from linked hospital admis-
sion data in the NSWAdmitted Patient Data Collection (APDC) of
the Admitted Patient, Emergency Department Attendance and
Deaths Register (APEDDR),5 accessed via Secure Analytics for
Population Health Research and Intelligence (SAPHaRI). The
APEDDR was established by the NSW Ministry of Health
under the Public Health Act 2010. NSW Central Cancer Registry
(CCR) data were analysed to assess the impact of resection on, University of South Australia, Adelaide, SA. 3Cancer Council Australia, Sydney, NSW.



















24post-diagnosis survival, as the CCR captures the date of diagnosis.
Cancer incidence data to 2009 (the latest year with complete inci-
dence data at the time of data extraction) were obtained from the
CCR; surgical information was obtained from linked APDC data.
Ethics approval for the CCReAPDC data linkage was obtained
from the NSW Population and Health Services Research Ethics
Committee (reference, HREC/12/CIPHS/58). The Centre for
Health Record Linkage performed the linkage using probabilistic,
privacy-preserving protocols (estimated false positive rate, 3 per
1000 records).Study population
The study population comprised NSW adults (aged 18 years
or more) diagnosed with pancreatic cancer (International
Classification of Diseases, 10th revision, Australian modification
[ICD-10-AM] code C25) between 2005 and 2013, excluding
neuroendocrine and other rare histological types. Residents of four
of the 15 regionswere excluded (12%of patients) because interstate
treatment resulted in incomplete capture of resection use.
Age at diagnosis, sex, primary tumour site, histology type and
region were obtained from the CCR and APDC. Charlson comor-
bidity scores were calculated from diagnoses recorded in the
patient’s first hospital admission for pancreatic cancer.6 For people
who underwent resection, Charlson score, procedure type, infor-
mation about whether vascular or arterial resection was under-
taken, urgency of admission, and urgency of procedure (the
emergency modifier of the anaesthetic procedure code) were
obtained for that admission.Outcomes
Resection use was classified using the Australian Classification of
Health Interventions block 978, “Pancreatectomy”. Post-operative
mortality within 90 days and one-year survival were determined
for patients who underwent pancreatectomy, with follow-up to
30 November 2013. Five-year post-diagnosis survival time was
calculated for people with a case recorded in the CCR,with follow-
up to 30April 2014.Dates of deathwere obtained from linkedNSW
Registry of Births Deaths and Marriages data and from the
National Death Index for CCR data. Linkage to theNational Death
Index was assisted by the Australian Institute of Health and
Welfare (AIHW) and was approved by the AIHW Ethics Com-
mittee (reference, EO 2014/2/89).Statistical analysis
The resection rates for Local Health Districts were the main study
factor, and were defined as the percentage of residents with
pancreatic cancerwhounderwent pancreatectomy,whether inside
or outside their region of residence. Regions were grouped into
categories according to resection rates (< 10%; 10e15%; > 15%) that
corresponded to lower, middle and higher resection rates in other
jurisdictions.7-9 The regions each managed public hospitals and
providedpublic outpatient andhealth support services, butdidnot
directly manage primary health care services. Private sector
hospital data were also included.
Variations between regions in resection rate were assessed by
multivariable logistic regression, adjusted for age, sex and Charl-
son score. The number of additional peoplewhowould be resected
if the 80th percentile regional rate applied in regions with lower
resection rates was calculated. A sensitivity analysis excluded
people aged 80 years or more to reduce the impact of differing
proportions of older people in the various regions.Associations between resection use by region and post-operative
90-day mortality and one-year survival were investigated,
adjusted for age at admission, sex, Charlson score, resection type
and urgency. A multi-level, cross-classified logistic model, with
region and hospital as random effects, was used because some
patients underwent surgery outside their region of residence. An
association between resection rate by region of residence and
5-year post-diagnosis survival rate was assessed with a Cox pro-
portional hazardsmodel with robust error estimation, adjusted for
age at diagnosis, sex and Charlson score. Cases with death
certificate-only notifications to the CCR (154 patients, 4%) were
excluded from post-diagnosis survival analyses because survival
times could not be defined. Risk-adjusted survival percentages
(with 95% confidence intervals [CIs]) were calculated with the
direct adjustment method.10
An association between resection rate andpancreatectomy volume
for pancreatic and periampullary cancers of hospitals within
regions was examined in a multilevel model that modelled the
relationship of the odds of resection with the maximum average
annual hospital volume, adjusting for patient age, sex and Charl-
son score.
Statistical analyses were conducted in Stata/MP 13.0 (StataCorp)
and SAS/Stat 12.1 (SAS Institute).
Results
Resection rates
Demographic and clinical characteristics of people diagnosedwith
pancreatic cancer in NSW during 2005e2013 are summarised in
Box 1. About 12% of people diagnosed during 2005e2009 under-
went pancreatectomy (APEDDR, 403 of 3473 patients); the pro-
portion increased to 14%during 2010e2013 (APEDDR, 431 of 3064
patients).
There was significant variation between regions in the odds of
resection in each study period, differences that remained after
adjusting for age, sex and Charlson score (P< 0.001). Five regions
remained in the same resection rate category across the two pe-
riods, and six regions moved to a higher resection rate category in
the second period. During 2010e2013, the proportion of patients
resected ranged between 8% and 21% (Box 2). If the 80th percentile
regional resection rate (18%) had applied in regions with lower
resection rates, an additional 32 people would have been resected
each year during 2010e2013. In the sensitivity analysis (excluding
people aged 80 years or more), the predicted number of additional
resections was 27.
Post-operative outcomes
Overall 90-day post-operative mortality during the 2005e2009
periodwas 6.5% (26 of 403 patients), comparedwith 4.8% (19 of 392
patients) for 2010e2013.Higher resection rateswere not associated
with increased 90-daymortality. For 2010e2013, the adjusted odds
ratios (aORs) for regions with resection rates of 10e15% or
> 15% (v regions with resection rates < 10%)were greater than one,
but these results were not statistically significant (Box 3).
Compared with regions with resection rates below 10%, one-
year post-operative survival during 2010e2013 was higher in
regions with 10e15% resection rates (aOR, 2.8; 95% CI, 1.2e6.4)
and was similar for regions with resection rates greater than
15% (aOR, 1.7; 95% CI, 0.8e3.6). Overall one-year post-
operative survival was 67.5% during 2005e2009 and
66.6% during 2010e2013 (Box 3).
1 Demographic and tumour characteristics of people with an incident case of pancreatic cancer, New South Wales,
2005e2013, recorded in the NSW Central Cancer Registry (CCR) or the Admitted Patient, Emergency Department







Total number 3552 3473 3064
Sex
Men 1798 (50.6%) 1771 (51.0%) 1577 (51.5%)
Women 1754 (49.4%) 1702 (49.0%) 1487 (48.5%)
Age at diagnosis/first admission
<60 years 552 (15.5%) 558 (16.1%) 494 (16.1%)
60e69 years 754 (21.2%) 758 (21.8%) 741 (24.2%)
70e79 years 1102 (31.0%) 1088 (31.3%) 869 (28.4%)
80 years 1144 (32.2%) 1069 (30.8%) 960 (31.3%)
Charlson comorbidity score (index admission)
0 2798 (78.8%) 2869 (82.6%) 2687 (87.7%)
1 235 (6.6%) 238 (6.9%) 135 (4.4%)
2 346 (9.7%) 366 (10.5%) 242 (7.9%)
No admission 173 (4.9%) — —
Primary site of tumour
Pancreas head (ICD-10-AM, C25.0) 1508 (42.5%) 1622 (46.7%) 1486 (48.5%)
Body and tail (ICD-10-AM, C25.1-2) 450 (12.7%) 481 (13.8%) 484 (15.8%)
Other pancreas (ICD-10-AM, C25.3e8) 188 (5.3%) 162 (4.7%) 155 (5.1%)
Pancreas, not otherwise specified (ICD-10-AM, C25.9) 1406 (39.6%) 1208 (34.8%) 939 (30.6%)
Histology
Adenocarcinoma 1963 (55.3%) 1592 (45.8%) 1621 (52.9%)
Unspecified 1589 (44.7%) 1525 (43.9%) 1065 (34.8%)
Unknown — 356 (10.3%) 378 (12.3%)
Extent
Local 552 (15.5%) — —
Regional 562 (15.8%) — —
Distant 1651 (46.5%) — —
Unknown 787 (22.2%) — —
Resection
Yes 435 (12.2%) 403 (11.6%) 431 (14.1%)
No 3117 (87.8%) 3070 (88.4%) 2633 (85.9%)
Region of residence resection rate
< 10% 671 (18.9%) 1147 (33.0%) 748 (24.4%)
10e15% 1960 (55.2%) 1800 (51.8%) 887 (28.9%)
> 15% 921 (25.9%) 526 (15.1%) 1429 (46.6%)


















25Vascular resection was not included in the risk adjustment models
because of recording differences between hospitals, but was noted
more frequently in pancreatectomy records from 2010e2013
(14.5%) than in those from 2005e2009 (8.2%).
Post-diagnosis survival
The 5-year survival rate after diagnosis was 5.1% (95% CI,
4.4e5.9) for people diagnosed during 2005e2009 (CCR data).
After adjusting for differences in age, sex and Charlson score,
survival was significantly higher (P< 0.001) in regions withhigher pancreatectomy rates (Box 4). Compared with regions
with resection rates below 10%, the risk-adjusted hazard ratio
for regions with a resection rate of 10e15% was 0.9 (95% CI,
0.8e0.9) and for regions with rates greater than 15% it was 0.7
(95% CI, 0.7e0.8). Risk-adjusted survival by region ranged
between 2.9% (95% CI, 1.9e4.5%) and 7.9% (95% CI, 6.3e9.9%;
Box 5). Assessing resection rate as a continuous variable, a
10-percentage point increase in the proportion of residents
resected corresponded to an estimated 16% reduction in the
5-year mortality rate (data not shown).
2 Proportion of residents in New South Wales administrative health regions (Local Health Districts) diagnosed with pancreatic
cancer who underwent resection, 2005e2009 and 2010e2013 (APEDDR data)*
A B
APEDDR¼Admitted Patient, Emergency Department Attendance and Deaths Register. *Regions are ordered by resection rate; the size of the symbols is proportional to the
number of cases of pancreatic cancer in a region. u
3 Post-operative pancreatectomy outcomes by regional resection rate, New South Wales, 2005e2013 (APEDDR data)
2005e2009 2010e2013*
90-day mortality One-year survival 90-day mortality One-year survival
% (n/N)
aORy
(95% CI) Pz % (n/N)
aORy
(95% CI) Pz % (n/N)
aORy
(95% CI) Pz % (n/N)
aORy
(95% CI) Pz


















































aOR¼adjusted odds ratio; APEDDR¼Admitted Patient, Emergency Department Attendance and Deaths Register; n¼number of deaths within 90 days (mortality) or people
alive at one year (survival); N¼ total number of pancreatectomies in resection rate category. *Resections to 1 September 2013 for 90-day mortality and to 30 November
2012 for one-year survival, to ensure complete follow-up. †Adjusted for sex, age group at admission, comorbidity status, type of surgery and urgency of admission for the
2005e2009 period, and urgency of procedure for the 2010e2013 period (the completeness of urgency of procedure data was insufficient for it to be included in models for the
2005e2009 period). ‡Wald test for categorical variables. u








ratio* (95% CI) Py
Resection rate <0.001
< 10% 631 1.9% (1.1e3.4) 3.4% (2.6e4.4) 1
10e15% 1888 5.7% (4.7e6.8) 5.2% (4.4e6.1) 0.9 (0.8e0.9)
> 15% 879 6.2% (4.8e8.0) 7.2% (6.0e8.7) 0.7 (0.7e0.8)
Total 3398 5.1% (4.4e5.9)




















Therewas a positive association between the odds of resection and
the maximum average annual hospital volume of pancreatectomyfor cancer by region (Box 6); the association for the period
2005e2009 was statistically significant (aOR, 1.06; 95% CI,
1.03e1.09; P<0.001) but not for 2010e2013 (aOR, 1.02; 95% CI,
5 Risk-adjusted 5-year post-diagnosis survival from
pancreatic cancer and regional resection rate, New
South Wales, 2005e2009 (CCR data, resected and
unresected patients)
CCR¼NSW Central Cancer Registry. The size of the symbols is proportional to the
number of cases of pancreatic cancer in a region. u
Research0.99e1.06; P¼ 0.16). During 2010e2013, six of the 11 regions had a
higher volume hospital (more than ten resections per year) within
their boundaries; a total of 39 NSW hospitals performed pancrea-
tectomy for cancer. On average, the residents with pancreatic
cancer in any region attended a total of ten different hospitals for
pancreatectomy during 2010e2013; 25e90% of patients6 Regional resection rate and maximum hospital volume of pan
New South Wales, 2005e2009 (A) and 2010e2013 (B) (APED
A B
APEDDR ¼ Admitted Patient, Emergency Department Attendance and Deaths Register. T
region; the blue area represents the proportion of administrative health region residents(dependingon the region)were resected in ahospital in their region
of residence. Fewer people underwent surgery in lower volume
hospitals (fewer than six resections per year) during 2010e2013 (89
of 431, 21%) than during 2005e2009 (166 of 403 resections, 41%).
Discussion
We identified regional differences in pancreatectomy rates that
were not explained by differences in age, sex or comorbidity status.
Fourteen per cent of people with pancreatic cancer underwent
pancreatectomy during 2010e2013, with regional rates ranging
between 8% and 21%. Post-operative outcomes in NSW compared
favourably with outcomes reported internationally,3,11 although
our NSW population figure for one-year post-operative sur-
vival (67%) was lower than that reported from an Australian
caseecontrol study (77%).12
We did not find an association between higher resection rates and
poorer post-operative outcomes up to one year after surgery.
Although the analyses of 90-day mortality may have been under-
powered for detecting clinically relevant differences, one-year
survival during 2010e2013 was greater in regions with higher
resection rates. Coupled with our finding that risk-adjusted 5-year
post-diagnosis survival was twice as high in regionswith resection
rates greater than15% than in thosewhere itwas less than 10% (Box
4), these results suggest thatmore resections could be performed in
NSWwithout harming post-operative outcomes, and that thismay
increase long term survival at the population level. We estimated
that an additional 32 people per year would be resected if rates in
lower rate regionswere increased to the 80th percentile level (18%),
an increase of 30% above the current annual average for our NSW
study area (108 resections for pancreatic cancer).
The resection rate we found is similar to published international
and national figures of about 15%.13,14 Apparent underuse of
pancreatectomy for pancreatic cancer at the population level, bycreatectomy for pancreatic and periampullary cancer,
DR data)
he size of the symbols is proportional to the number of cases of pancreatic cancer in a




































28geographic region, or across socio-demographic groups has been
described in the United States, the United Kingdom, and else-
where.3,7-9,15,16 System-related factors at the primary and tertiary
care levels and patient-related factors may all affect the accessi-
bility and uptake of pancreatic surgery.
At the individual level, disparity in outcomes have been reported
for patients with pancreatic and other cancers that was related to
geographic remoteness and socio-demographic factors.15-17 Even
when reviewed at a specialist service, the uptake of treatment by
people at greater social disadvantage can be lower.15,18,19 One-fifth
of people with resectable pancreatic cancer in NSW and Queens-
land were reported to have declined surgery.14 We chose not to
adjust our analyses for remoteness, socio-economic status or
country of birth because associated risk factors, such as accept-
ability of services and health literacy, may be modifiable. Factors
that reduce access to treatment need to be identified so that prac-
ticable advice can be delivered to health care providers and policy
makers.
At the primary care level, referral pathwaysmay affect the number
of people receiving staging and surgical evaluation in multidisci-
plinary settings. Few studies have examined the impact of primary
care referral on treating pancreatic and other cancers. A US study
reported that people with loco-regional pancreatic cancer who had
a regular primary care doctor were 37% more likely to receive
surgical evaluation, reflecting the positive influence of primary
care.15 A strong operational link between primary care and
multidisciplinary care is needed to optimise cancer treatment
outcomes,20 especially for cancers that will rarely be encountered
by primary care physicians in a lifetime of work.
At the hospital level, careful patient selection that balances the
potential benefits and risks at the individual level will depend on
the available services and expertise in pancreatico-biliary and
vascular surgery, interventional radiology, anaesthesia, rehabili-
tation, and the management of comorbidities. Pre-operative stag-
ing with specialist imaging and multidisciplinary review,
including pancreatico-biliary surgeons, is important for identi-
fying andplanning resections of tumourswith vascular or adjacent
organ involvement, and can reduce the number of incomplete
resections by identifying unresectable disease early.20,21 A recent
study in Queensland and NSW reported that 24% of attempted
resections were not completed,14 while another reported a higher
completion rate in Queensland hospitals with higher pancreatec-
tomy volumes.12We found a positive association between regional
resection rate and hospital volume of pancreatectomy for cancer.An extensive literature has reported higher mortality in lower
volume hospitals performing complex pancreatic surgery;22 a
recent Australian study found an association between lower
volume surgeons and poorer outcomes.23 In addition to mortal-
ity, other crucial quality measures include access to multidisci-
plinary services, complication rates, and time from operation to
adjuvant therapy.24,25 Standardised data collection, analysis and
national reporting would help elucidate the reasons for variations
in practice.
The clinical details available to us in this study were limited.
Information on clinical staging, adjuvant therapy, multidisci-
plinary team referral, patient contraindications for surgery, access
of patients to health services and their treatment preferences are
needed to assess their impact on resection use and long term
survival. The strengths of our study were that it was population-
based and spanned 9 years of care to 2013. Our findings
therefore reflect current surgical rates and outcomes for people
diagnosed with pancreatic cancer in NSW.
Our results indicate that in some areas of NSW patients who may
potentially benefit from pancreatectomy are not receiving it. The
finding that overall survival from pancreatic cancer was higher in
regionswith higher resection rates is important, as optimising the
use of resection has the potential to improve survival at the
individual and population levels.7 Increasing knowledge and
awareness of hospitals with the expertise and resources for
managing complex cases should enable more people to undergo
surgery. In NSW, regions face different and unequal challenges in
providing equity of access to multidisciplinary care. Although
there is a compelling case for reducing the number of sites per-
forming pancreatic cancer surgery in NSW, as has been described
for other cancer surgery types,26 there are geographic and socio-
demographic barriers to doing so. There also needs to be a
whole-of-system approach, linking primary and tertiary care, as
well as patient information and support, to optimise outcomes for
patients.
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